NOMO1
BOS complex subunit NOMO1
Also known as: NOMO1_HUMAN, PM5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q15155
- Gene
- NOMO1
- Ensembl
- ENSG00000103512
- Chromosome
- 16
- Canonical length
- 1222 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Endoplasmic reticulum
OverviewNCBI Gene
This gene encodes a protein originally thought to be related to the collagenase gene family. This gene is one of three highly similar genes in a region of duplication located on the p arm of chromosome 16. These three genes encode closely related proteins that may have the same function. The protein encoded by one of these genes has been identified as part of a protein complex that participates in the Nodal signaling pathway during vertebrate development. Mutations in ABCC6, which is located nearby, rather than mutations in this gene are associated with pseudoxanthoma elasticum (PXE). [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1222 residues, UniProt reviewed canonical sequence.
>Q15155|NOMO1
1 MLVGQGAGPL GPAVVTAAVV LLLSGVGPAH GSEDIVVGCG GFVKSDVEIN YSLIEIKLYT
61 KHGTLKYQTD CAPNNGYFMI PLYDKGDFIL KIEPPLGWSF EPTTVELHVD GVSDICTKGG
121 DINFVFTGFS VNGKVLSKGQ PLGPAGVQVS LRNTGTEAKI QSTVTQPGGK FAFFKVLPGD
181 YEILATHPTW ALKEASTTVR VTNSNANAAS PLIVAGYNVS GSVRSDGEPM KGVKFLLFSS
241 LVTKEDVLGC NVSPVPGFQP QDESLVYLCY TVSREDGSFS FYSLPSGGYT VIPFYRGERI
301 TFDVAPSRLD FTVEHDSLKI EPVFHVMGFS VTGRVLNGPE GDGVPEAVVT LNNQIKVKTK
361 ADGSFRLENI TTGTYTIHAQ KEHLYFETVT IKIAPNTPQL ADIIATGFSV CGQISIIRFP
421 DTVKQMNKYK VVLSSQDKDK SLVTVETDAH GSFCFKAKPG TYKVQVMVPE AETRAGLTLK
481 PQTFPLTVTN RPMMDVAFVQ FLASVSGKVS CLDTCGDLLV TLQSLSRQGE KRSLQLSGKV
541 NAMTFTFDNV LPGKYKISIM HEDWCWKNKS LEVEVLEDDM SAVEFRQTGY MLRCSLSHAI
601 TLEFYQDGNG RENVGIYNLS KGVNRFCLSK PGVYKVTPRS CHRFEQAFYT YDTSSPSILT
661 LTAIRHHVLG TITTDKMMDV TVTIKSSIDS EPALVLGPLK SVQELRREQQ LAEIEARRQE
721 REKNGNEEGE ERMTKPPVQE MVDELQGPFS YDFSYWARSG EKITVTPSSK ELLFYPPSME
781 AVVSGESCPG KLIEIHGKAG LFLEGQIHPE LEGVEIVISE KGASSPLITV FTDDKGAYSV
841 GPLHSDLEYT VTSQKEGYVL TAVEGTIGDF KAYALAGVSF EIKAEDDQPL PGVLLSLSGG
901 LFRSNLLTQD NGILTFSNLS PGQYYFKPMM KEFRFEPSSQ MIEVQEGQNL KITITGYRTA
961 YSCYGTVSSL NGEPEQGVAM EAVGQNDCSI YGEDTVTDEE GKFRLRGLLP GCVYHVQLKA
1021 EGNDHIERAL PHHRVIEVGN NDIDDVNIIV FRQINQFDLS GNVITSSEYL PTLWVKLYKS
1081 ENLDNPIQTV SLGQSLFFHF PPLLRDGENY VVLLDSTLPR SQYDYILPQV SFTAVGYHKH
1141 ITLIFNPTRK LPEQDIAQGS YIALPLTLLV LLAGYNHDKL IPLLLQLTSR LQGVRALGQA
1201 ASDNSGPEDA KRQAKKQKTR RTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NOMO1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 133 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 133 nTPM
- skeletal muscle: 101 nTPM
- heart muscle: 89 nTPM
- basal ganglia: 72 nTPM
- cerebral cortex: 56 nTPM
- cerebellum: 48 nTPM
Single-cell type
- oligodendrocytes: 33 nCPM
- platelets: 30 nCPM
- adrenal medulla cells: 21 nCPM
- distal convoluted tubule cells: 19 nCPM
- loop of henle epithelial cells: 18 nCPM
- oligodendrocyte progenitor cells: 17 nCPM
Immune cell
- basophil: 3.7 nTPM
- non-classical monocyte: 2 nTPM
- NK-cell: 1.8 nTPM
- plasmacytoid DC: 1.6 nTPM
- neutrophil: 0.6 nTPM
- total PBMC: 0.6 nTPM
Brain region
- hypothalamus: 14 nTPM
- cerebral cortex: 2.5 nTPM
- white matter: 2.3 nTPM
- medulla oblongata: 2 nTPM
- pons: 1.8 nTPM
- cerebellum: 1.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.02
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.52
- DepMap mean gene effect
- 0
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Carboxypeptidase-like, regulatory domain superfamily
- Immunoglobulin-like fold
- Carbohydrate-binding-like fold
- SpaA-like, prealbumin fold domain subgroup 1
- Serine-Aspartate Repeat-Containing
- NOMO-like, ninth beta-sandwich domain
- NOMO-like, N-terminal beta-sandwich domain
- NOMO, eighth prealbumin-like domain
- NOMO, third transthyretin-like domain
- NOMO, fifth transthyretin-like domain
- NOMO, C-terminal transthyretin-like domain
- NOMO, seventh transthyretin-like domain
- Carboxypeptidase regulatory-like domain
- Prealbumin-like fold domain
- BOS complex subunit NOMO1-like, first beta sandwich domain
- BOS complex subunit NOMO1-like, beta sandwich domain
- BOS complex subunit NOMO1-like, second beta sandwich domain
- NOMO Ig-like domain
- NOMO C-terminal transthyretin-like domain
- NOMO third transthyretin-like domain
- NOMO fifth transthyretin-like domain
- NOMO eighth prealbumin-like domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NOMO1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NOMO1 as an antibody target. Whether an autoantibody or antibody against NOMO1 could matter depends on whether native NOMO1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NOMO1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NOMO1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...